US Patent

US10124014 — Minocycline compounds and methods of use thereof

Method of Use · Assigned to Paratek Pharmaceuticals Inc · Expires 2029-03-05 · 3y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a method of treating bacterial infections, including MSSA, MRSA, and others, using the drug 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof.

USPTO Abstract

Methods and compositions for using a tetracycline compound to treat bacterial infections are described. In one embodiment, for example, the invention provides a method of treating a subject for an infection, comprising administering to said subject an effective amount of 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof, such that said subject is treated, wherein said infection is selected from the group consisting of MSSA, MRSA, B-streptococci, Viridans Streptococci, Enterococcus, or combinations thereof.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-2449 — Nuzyra
U-2449 — Nuzyra

Patent Metadata

Patent number
US10124014
Jurisdiction
US
Classification
Method of Use
Expires
2029-03-05
Drug substance claim
No
Drug product claim
No
Assignee
Paratek Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.